NCT03593421View on ClinicalTrials.gov

Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 31, 2020

Conditions
Panel Reactive Antibodies
Interventions
DRUG

synthetic PreImplantation Factor

peptide

Sponsors

Collaborators (1)

BioIncept LLC
All Listed Sponsors
collaborator

BioIncept LLC

INDUSTRY

lead

Christopher O'Brien, MD

OTHER

NCT03593421 - Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies | Biotech Hunter | Biotech Hunter